2-硫代-2’-脱氧胸苷 | 28585-51-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 2-硫代-2’-脱氧胸苷
• 中文别名: 2-硫代胸苷；2-硫代-2'-脱氧胸苷
• 英文名称: 2-thiothymidine
• 英文别名: β-2-Thio-thymidin；2-Thiothymidin；1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one
• CAS: 28585-51-5
• 化学式: C₁₀H₁₄N₂O₄S
• 分子量: 258.298
• InChiKey: PISWNSOQFZRVJK-XLPZGREQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  5

制备方法与用途

硫代胸苷是一种嘌呤核苷类似物，而嘌呤核苷类似物广泛具有抗肿瘤活性，尤其是针对惰性淋巴系统恶性肿瘤。其抗癌机制主要通过抑制DNA合成和诱导细胞凋亡来实现。

反应信息

• 作为反应物：
  描述：

  2-硫代-2’-脱氧胸苷 在 Raney nickel 作用下， 以 水 为溶剂， 反应 2.0h， 以50%的产率得到2’-deoxy-5-methyl-4-pyrimidinone
  参考文献：
  名称：

  Polymerase recognition of 2-thio-iso-guanine·5-methyl-4-pyrimidinone (iGs·P)—A new DD/AA base pair

  摘要：

  Polymerase specificity is reported for a previously unknown base pair with a non-standard DD/AA hydrogen bonding pattern: 2-thio-iso-guanine center dot 5-methyl-4-pyrimidinone. Our findings suggest that atomic substitution may provide a solution for low fidelity previously associated with enzymatic copying of iso-guanine. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.01.041
• 作为产物：
  描述：

  3’-O-acetyl-2,5’-anhydrothymidine 在 硫化氢 、 氨 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-硫代-2’-脱氧胸苷
  参考文献：
  名称：

  Polymerase recognition of 2-thio-iso-guanine·5-methyl-4-pyrimidinone (iGs·P)—A new DD/AA base pair

  摘要：

  Polymerase specificity is reported for a previously unknown base pair with a non-standard DD/AA hydrogen bonding pattern: 2-thio-iso-guanine center dot 5-methyl-4-pyrimidinone. Our findings suggest that atomic substitution may provide a solution for low fidelity previously associated with enzymatic copying of iso-guanine. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.01.041

文献信息

• POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
  申请人：TRANSLATE BIO, INC.

  公开号：US20200277446A1

  公开（公告）日：2020-09-03

  Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.

  揭示了包含A基团的聚合物，该基团是化学式I的基团：及其药用可接受的盐，其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
• [EN] COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF<br/>[FR] COMPOSÉS COMPRENANT UN LIEUR CLIVABLE ET LEURS UTILISATIONS
  申请人：INTOCELL INC

  公开号：WO2019008441A1

  公开（公告）日：2019-01-10

  Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

  提供了一种包括可切割连接物的化合物，其用途，以及用于制备该化合物的中间体化合物，更具体地，本发明的包括可切割连接物的化合物可能包括具有特定功能或活性的活性剂（例如，药物，毒素，配体，用于检测的探针等），能够选择性释放活性剂的SO2官能团，以及通过外部刺激触发化学反应，物理化学反应和/或生物反应的官能团，并且还可以包括具有与所需靶受体结合特异性的配体（例如，寡肽，多肽，抗体等）。
• [EN] BINDING-SITE MODIFIED LECTINS AND USES THEREOF<br/>[FR] LECTINES DE SITE DE LIAISON MODIFIÉES ET USAGE CORRESPONDANT
  申请人：SMARTCELLS INC

  公开号：WO2010088261A1

  公开（公告）日：2010-08-05

  In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.

  在一个方面，该公开提供了包括多价凝集素的交联材料，其中该多价凝集素具有至少两个葡萄糖结合位点，其中该凝集素包括至少一个与亲和配体共价连接的亲和配体，该亲和配体能够与至少一个所述结合位点中的葡萄糖竞争结合；以及包括绑定到共轭框架的两个或更多个独立亲和配体的共轭物，其中这两个或更多个亲和配体与葡萄糖在所述结合位点上与凝集素竞争结合，其中由于不同共轭物上的凝集素和亲和配体之间的非共价相互作用，共轭物在材料内交联。这些材料旨在根据所需葡萄糖浓度释放共轭物的量。根据最终应用，在各种实施例中，共轭物还可以包括药物和/或可检测标记。
• [EN] CATIONIC LIPIDS COMPRISING AN HYDROXY MOIETY<br/>[FR] LIPIDES CATIONIQUES COMPRENANT UNE FRACTION HYDROXY
  申请人：TRANSLATE BIO INC

  公开号：WO2020257611A1

  公开（公告）日：2020-12-24

  Disclosed are lipids which are compounds of Formula I. Lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

  本文披露的是化合物I的脂质。本文提供的脂质可用于传递和表达mRNA和编码蛋白，例如作为脂质体传递载体的组分，因此可用于治疗与一种或多种蛋白质缺乏相关的各种疾病、紊乱和症状。
• [EN] CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2014179620A1

  公开（公告）日：2014-11-06

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供了具有共轭基团的寡聚化合物。在某些实施例中，这些寡聚化合物与N-乙酰半乳糖结合。